Join Factor Bioscience and become part of a team working to invent new technologies to treat disease and improve health.
Our research lab and ISO Class 7 cleanroom facility are both located at our headquarters in Cambridge, Massachusetts.
Associate Scientist
Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist. In this position, you will create advanced mRNA and cell-engineering technologies for the development of new medicines for patients with devastating diseases including Parkinson's disease, Crohn's disease, dystrophic epidermolysis bullosa, and cancer.
Associate Scientist (Chemistry)
Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist. In this position, you will create advanced mRNA and cell-engineering technologies for the development of new medicines for patients with devastating diseases including Parkinson's disease, Crohn's disease, dystrophic epidermolysis bullosa, and cancer.
April 23, 2024
Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
-Factor to reveal novel mRNA-engineered immunosuppressive allogeneic cells. -Presentations will include latest data from Factor’s library of novel ionizable lipids, including delivery of mRNA to T cells and monocytes. -Factor to present progress on multi-cell type iPS cell strategy for solid-tumor targeting, including mRNA engineering for enhanced cancer-cell killing. CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ […]
April 9, 2024
Factor Bioscience Expands Translational Science Team, Appoints Kyle Garland, Ph.D., as Director of Translational Science
CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ — Factor Bioscience Inc. (“Factor”), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science. “We are excited to welcome […]
January 9, 2024
Factor Bioscience Announces U.S. Department of Defense Grant to Develop Gene-Edited Cell Therapies
-Leverages Factor’s extensively patented mRNA, cell-reprogramming, and gene-editing technologies -Cell therapy candidates will initially be developed for the treatment of Duchenne muscular dystrophy (“DMD”) -Other planned applications include infectious, inflammatory, and autoimmune indications CAMBRIDGE, Mass., January 9, 2024 /PRNewswire/ — Factor Bioscience Inc. (“Factor”), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, announced […]